UTAH MEDICAL PRODUCTS INC

Utah Medical Products reported a 10.2% decrease in Q1 2026 net sales to $8.72 million and an 11.0% decline in diluted EPS to $0.818 compared to Q1 2025. The sales decline was primarily due to the expected absence of sales to its former largest China distributor and OEM customer PendoTECH. Despite lower sales, the gross profit margin improved to 60.6%, though operating income was impacted by higher litigation and employee healthcare costs. The company maintained a strong balance sheet, increasing cash and investments by $4.08 million year-over-year, and continued share repurchases and dividend payments.

Utah Medical Products, Inc. announced its financial performance for the first quarter ended March 31, 2026. The company also provided forward-looking statements for 2026 and beyond. Detailed financial information was presented in a press release dated April 23, 2026, which is incorporated by reference as Exhibit 99.1 to this filing.